Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 56,000 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 56,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total value of $6,475,280.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $8,566,679.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

TransMedics Group Stock Performance

TMDX stock opened at $127.99 on Monday. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $129.66. The business’s fifty day simple moving average is $85.54 and its two-hundred day simple moving average is $77.32. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The business had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The company’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period last year, the company posted ($0.08) earnings per share. Analysts predict that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Morgan Stanley raised their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. TD Cowen boosted their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Oppenheimer increased their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Piper Sandler restated an “overweight” rating and issued a $120.00 target price (up from $95.00) on shares of TransMedics Group in a report on Wednesday, May 1st. Finally, Canaccord Genuity Group upped their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $119.00.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently made changes to their positions in the company. Venturi Wealth Management LLC bought a new stake in shares of TransMedics Group in the first quarter valued at about $30,000. Fidelis Capital Partners LLC purchased a new position in TransMedics Group during the 1st quarter valued at about $35,000. Cutler Group LLC CA raised its holdings in shares of TransMedics Group by 600.0% in the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares in the last quarter. RiverPark Advisors LLC purchased a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $60,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.